Halt cardiomyOPathy progrEssion in Duchenne (HOPE-OLE)

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 21, 2018

Primary Completion Date

March 6, 2019

Study Completion Date

March 6, 2019

Conditions

Duchenne Muscular Dystrophy

Interventions

BIOLOGICAL

Allogeneic Cardiosphere-Derived Cells (CAP-1002)

Intravenous infusion delivery of Allogeneic Cardiosphere-Derived Cells (CAP-1002; 75 million CDCs)

Trial Locations (2)

University of Florida, Gainesville

Cincinnati Children's Medical Center, Cincinnati

All Listed Sponsors

lead

Capricor Inc.

INDUSTRY

NCT06304064 - Halt cardiomyOPathy progrEssion in Duchenne (HOPE-OLE) | Biotech Hunter | Biotech Hunter